Company: OSRH
Filing Date: 2025-06-23
Form Type: 424B3
Source: 0001213900-25-056351
Chunk: 8

Company: OSR Holdings, Inc.
Filing Date: 2025-06-23
Form: 424B3
Chunk 8
---
 We evaluate
our subsidiary candidate opportunities by better understanding the target indications toward identifying new approaches and technologies
to improve treatment outcomes. We collaborate with academic and industry leaders to promote a seamless integration and partnership between
entrepreneurial scientists and seasoned business development and leadership teams. These technical and scientific experts from academia
and industry bring innovative contributions and a high level of enthusiasm. Our holding company leadership team supports and empowers
each subsidiary to transform their potentially breakthrough discoveries into impactful and viable commercial products.

Our company’s collective expertise from
industry veterans, seasoned scientists, capital market and legal professionals provides the core foundation of our global healthcare
holding company. the Company operates as a hub-and-spoke business model with a centralized executive team partnering with subsidiary
management teams to ensure overall program and corporate alignment by and between subsidiaries and holding company. Our overarching goal
is to enhance value creation for our subsidiaries by continuously assessing optimal development options and exploring partnership and
fundraising opportunities. We encourage cooperation and knowledge sharing among our subsidiaries to enhance our synergistic business
model. We believe our strong foundational scientific conviction, entrepreneurial acumen and opportunistic approach positions us as a
differentiated global company advancing pharmaceutical and medical device technologies in an efficient, cost-effective and meaningful
manner. Our interdisciplinary team of accomplished scientists and entrepreneurial business leaders promotes the development and commercialization
of a risk diversified portfolio to address unmet medical needs with resilience and efficiency.

<div align='center'>1</div>

Our corporate organization and ownership of subsidiaries is illustrated by the following chart*: Portfolio Overview OSR’s subsidiaries (other than RMC) have diverse scientific and technological developments and are engaged in distinct areas of therapeutics research and development, including oral T-cell immunotherapies and recombinant biologics. This approach not only provides the Company with a broader scope of potential therapeutic solutions but also reduces the risks associated with a singular-asset approach. Figure 2 below summarizes our three subsidiaries, two of which have their own drug development pipelines.

| Portfolio Company |     | Science, Technology and Platform                                                                                                 |
|                   |     | T-cell immunotherapies based on a live attenuated,                                                                               
 safe, orally, available bacterial vaccine strain, genetically modified to develop and elicit patients’ cytotoxic T-cells against 
 specific pre-defined targets                                                                                                     |
|                   |     | Platform integrating different protein domain sequences                                                                          
 linking into a Design augmented recombinant biologic with enhanced biological functionality                                      |
|                   |     | Neurovascular surgical devices                                                                                                   |

Figure 2